



- (51) **International Patent Classification:**
A61K 47/48 (2006.01) *C07K 5/02* (2006.01)
- (21) **International Application Number:**
PCT/US2014/070800
- (22) **International Filing Date:**
17 December 2014 (17.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/917,293 17 December 2013 (17.12.2013) US
- (71) **Applicant (for all designated States except US):** **IRM LLC** [US/—]; 131 Front Street, PO Box HM 2899, Hamilton, HM LX (BM).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** **GEIERSTANGER, Bernhard** [DE/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **GRUNEWALD, Jan** [DE/US]; c/o

Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **OU, Weijia** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **ONO, Tetsuo** [JP/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **WAN, Yongqin** [US/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **WANG, Xing** [CN/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **JIN, Yunho** [KR/US]; c/o Novartis Institute for Functional Genomics, Inc., Genomics Institute of the Novartis Research Foundation (GNF), 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

[Continued on next page]

- (54) **Title:** CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF





FIG. 6A



(57) **Abstract:** Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: Formula (I) and the use of such peptides in making immunoconjugates (i.e. Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e. Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.



(74) **Agent:** RAYMOND, Daniel E.; c/o Novartis Pharmaceuticals Corporation, IP Services Mail Data, One Health Plaza 101/2, East Hanover, New Jersey 07936 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report:**

3 September 2015